MARKET WIRETradingView • 7h ago
Zevra Therapeutics, Inc. Estimates – NASDAQ:ZVRATradingView report covering Zevra Therapeutics Inc. (ZVRA) market action, institutional positioning, and fundamental catalysts.
Why ZVRA Stock slipped -0.77% Today — RQD Quant Desk Flash
$10.28 -0.77% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $10.25
Zevra Therapeutics Inc. (ZVRA) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $615.2M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on ZVRA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is ZVRA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Zevra Therapeutics Inc. (NASDAQ: ZVRA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $10.28 (-0.77% 1D, market cap $615.2M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, ZVRA ranks #606 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does ZVRA compare to GERN and NVCT in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ZVRA carries a Roarable D- (37/100 RQD), trailing P/E of 7.4x, gross margin of —, and ROIC of -32.3%. By comparison, GERN (Geron Corporation) holds a E grade (29/100 RQD, P/E N/A, ROIC -20.2%, cap $607.9M) and NVCT (Nuvectis Pharma Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $605.6M). Among the 5-stock peer group, CRMD leads on earnings multiple (3.7x) while IRWD leads on capital efficiency (85.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for ZVRA?
▼
Per ZVRA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001434647), Zevra Therapeutics Inc. generated $0 in revenue, $83.2M in net income, and -$2.4M in free cash flow against $284.7M in total assets and $61.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $10.25 (-0.33%)🧬 Dilution Drag (+1.36% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-9.4% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ZVRA)Realized 20D OHLCV Swing Band: ±9.2%
Deterministic 5-Pillar Attribution (37/100 Composite)
🔍 WHY ZVRA SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (35% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (19% of score)
FRED Regime × Technicals: 32% of 52W Range • RSI-14 at 47 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)
Capital intensity & 0% operating margin leave 16 pts on the table
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$11.32-10.2% Next Q
45
Q2 (-2Q)Grade D$10.16-6.2% Next Q
42
Q3 (-1Q)Grade D$9.53+7.9% Next Q
40
CurrentGrade D-$10.28-8.1% Hist 90D α
37
Trajectory: D (45) → D- (37)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a ZVRA Turnaround Squeeze
While ZVRA currently carries a cautious 37/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($11.15) and Max Pain ($10.79) forces dealer call-delta covering toward $15.78.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.36% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ZVRA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ZVRA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ZVRA Stock slipped -0.77% Today — RQD Quant Desk Flash
Zevra Therapeutics Inc. (ZVRA) slipped -0.77% to $10.28, trading at 32% of its 52-week range ($8.01 – $15.03). Stretched risk/reward at 7x P/E (-32% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 32% of its 52-week range ($8.01 – $15.03) with RSI-14 at 47 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±9.2% around $10.28 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live ZVRA Headlines & Catalysts
MARKET WIRESeeking Alpha • 10h ago
Zevra Therapeutics: Cash Plus A Drug Priced Below Its Rival's Deal (NASDAQ:ZVRA)Seeking Alpha report covering Zevra Therapeutics Inc. (ZVRA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 13h ago
A 20,000-share sale was reported by Zevra Therapeutics (ZVRA) director Neil F. McFarlane.Stock Titan report covering Zevra Therapeutics Inc. (ZVRA) market action, institutional positioning, and fundamental catalysts.
CATALYSTStocktwits • 16h ago
ZVRA Stock Hits Its Highest Levels In Nearly 5 Years – What’s Driving This Sharp Rally Today?Stocktwits report covering Zevra Therapeutics Inc. (ZVRA) market action, institutional positioning, and fundamental catalysts.
CATALYSTSeeking Alpha • 19h ago
Zevra Therapeutics: Miplyffa Validates The Bull Case, Europe Still The Swing Factor (ZVRA)Seeking Alpha report covering Zevra Therapeutics Inc. (ZVRA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com Canada • 22h ago
Zevra Therapeutics president and CEO sells $224,948 in stock By Investing.comInvesting.com Canada report covering Zevra Therapeutics Inc. (ZVRA) market action, institutional positioning, and fundamental catalysts.
CATALYSTTradingView • 1d ago
Zevra Therapeutics, Inc. Stock 12‑Month Price Target Raised to $25.25, Implies 146% UpsideTradingView report covering Zevra Therapeutics Inc. (ZVRA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREThe Manila Times • 1d ago
Zevra Therapeutics Announces Details for Q3 2026 Financial Results CallThe Manila Times report covering Zevra Therapeutics Inc. (ZVRA) market action, institutional positioning, and fundamental catalysts.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ZVRA)
- ✓Walkthrough of ZVRA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ZVRA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +2.29%📐 WEDGE COMPRESSION COIL
2026-11-02O $10.31H $10.36L $10.28C $10.28VOL 507.9K
RES: $10.97SUP: $9.49SMA50: $11.15SMA200: $10.75
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ZVRA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
-6.9%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on ZVRA today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ZVRA. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ZVRA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ZVRA)
Health Care Rank #606 of 1016
⚔️ GERN vs ZVRA Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ZVRA vs. GERN, NVCT, IRWD, CRMD)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Zevra Therapeutics Inc. (ZVRA) ranks #606 by composite RQD confidence (37/100, grade D-) and #417 by equity capitalization ($615.2M). Within this direct 5-issuer industry benchmark cohort, CRMD leads on earnings valuation at 3.7x trailing P/E, while IRWD leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. IRWD currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with ZVRA at 37/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ZVRA
ACTIVE
Zevra Therapeutics Inc. | D- | 37/100 | 7.4x | — | -32.3% | -0.77% | $615.2M | Benchmark Subject |
| GERN Geron Corporation | E | 29/100 | — | — | -20.2% | -5.47% | $607.9M | /gern-vs-zvra → |
| NVCT Nuvectis Pharma Inc. | D- | 37/100 | — | — | -35.0% | -0.48% | $605.6M | /nvct-vs-zvra → |
| IRWD Ironwood Pharmaceuticals Inc. (Class A) | C | 63/100 | 24.9x | — | 85.0% | -3.31% | $598.2M | /irwd-vs-zvra → |
| CRMD CorMedix Inc. | C | 62/100 | 3.7x | 88.5% | 45.5% | -25.46% | $595.5M | /crmd-vs-zvra → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001434647In its most recent audited fiscal period (FY2025, filed 2025-12-31), Zevra Therapeutics Inc. (ZVRA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of $83.2M, operating cash flow of -$1.6M, and free cash flow of -$2.4M (+96.5% YoY). On the balance sheet, ZVRA closed FY2025 with $284.7M in total assets against $61.9M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | $83.2M | -$1.6M | -$2.4M | $284.7M | $61.9M |
| FY2024 (FY) | 2024-12-31 | $0 | -$105.5M | -$69.7M | -$69.7M | $178.1M | $59.5M |
| FY2023 (FY) | 2023-12-31 | $0 | -$46.0M | -$33.5M | -$33.5M | — | — |
3. ZVRA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ZVRA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Zevra Therapeutics Inc. (NASDAQ: ZVRA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $10.28 (-0.77% 1D, market cap $615.2M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, ZVRA ranks #606 in composite RQD confidence.
How does ZVRA compare to GERN and NVCT in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ZVRA carries a Roarable D- (37/100 RQD), trailing P/E of 7.4x, gross margin of —, and ROIC of -32.3%. By comparison, GERN (Geron Corporation) holds a E grade (29/100 RQD, P/E N/A, ROIC -20.2%, cap $607.9M) and NVCT (Nuvectis Pharma Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $605.6M). Among the 5-stock peer group, CRMD leads on earnings multiple (3.7x) while IRWD leads on capital efficiency (85.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ZVRA?
Per ZVRA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001434647), Zevra Therapeutics Inc. generated $0 in revenue, $83.2M in net income, and -$2.4M in free cash flow against $284.7M in total assets and $61.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ZVRA trading relative to its 50-day, 200-day, and 52-week technical levels?
ZVRA last traded at $10.28 (-0.77% on volume of 642,059 shares), positioning the stock -7.80% below its 50-day simple moving average ($11.15) and -4.37% below its 200-day simple moving average ($10.75). Across its 52-week range of $8.01 to $15.03, ZVRA sits at the 32.3% percentile with a 14-day RSI of 47.0 (NEUTRAL RANGE) and an implied next-earnings move of ±9.2% ($9.33 to $11.23).
ZVRA Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is ZVRA stock moving today?
Why ZVRA Stock slipped -0.77% Today — RQD Quant Desk Flash. Stretched risk/reward at 7x P/E (-32% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 37/100 (D-)
✓ STAGE-C NUMBER FIREWALL VERIFIED
ZVRA — Zevra Therapeutics Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:34:28Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, ZVRA scores 37 out of 100 with a letter grade of D- and a verdict label of "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:
- Fundamental Cash Engine (4 / 20): Per the Roarable RQD rating, this is the weakest pillar, reflecting ROIC of -32.3% and FCF yield of -0.4%. For a prospective investor, this means the business is not currently generating returns on invested capital or positive free cash flow to support its valuation on cash-flow grounds.
- Whale 13F Flow (6 / 20): Per the Roarable RQD rating, institutional accumulation and options positioning score weakly. Investors should not read this as confirmation of institutional conviction.
- Insider Conviction (7 / 20): Per the Roarable RQD rating, SEC Form 4 and Congressional PTR cluster flow score weakly. Recent news items reference insider sales, which the rating does not treat as supportive.
- Macro Regime Fit (7 / 20): Per the Roarable RQD rating, beta of 1.0 and sector sensitivity score weakly. The stock's market-relative volatility is in line with the market, offering no defensive cushion in a risk-off regime.
- Forensic Balance Sheet (13 / 20): Per the Roarable RQD rating, Altman Z of 2.5, Piotroski F of 4/9, and Debt/Equity of 0.4 are the strongest pillar, though still moderate. This is the most constructive pillar in the rating.
Taken together, the rating implies a valuation that is low on earnings multiples (P/E 7.4 TTM) while the underlying operating cash engine remains negative. Upside drivers would need to come from a sustained improvement in operating returns and free cash flow; the source data does not indicate that such a turn has occurred. Investors weighing the low multiple against negative ROIC should recognize the tradeoff: earnings-based cheapness can coexist with weak cash generation. This is educational analysis, not personalized financial advice.
Business
Zevra Therapeutics Inc. (ZVRA) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry, per the company profile. Per the company profile, the company has a market capitalization of $0.6B. The source data does not describe the company's products, customers, or revenue model in detail.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-62.9M | $83.2M | N/A | $-2.4M | $62.4M | $61.9M |
| FY 2024 | $0.0M | $-87.0M | $-105.5M | N/A | $-69.7M | $33.8M | $59.5M |
| FY 2023 | $0.0M | $-49.6M | $-46.0M | N/A | $-33.5M | N/A | N/A |
Per the SEC financials, reported revenue is $0.0M across the periods shown, and operating income is negative in each. Per the market data, gross, operating, and net margins are each 0%, and ROIC is -32.3%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 4/9. Per the Roarable RQD rating, Debt/Equity is 0.4. FY 2025 shows net income of $83.2M despite negative operating income of $-62.9M, a divergence the source data does not explain.
Recent Catalysts & News Wire Analysis
Per the recent news feed, the items are:
- Market-wire coverage of ZVRA estimates (TradingView, marked YELLOW).
- A Seeking Alpha piece on cash position relative to a rival's deal pricing (YELLOW).
- A Stock Titan report of a 20,000-share sale by director Neil F. McFarlane (YELLOW).
- A Stocktwits report on the stock reaching its highest levels in nearly five years (GREEN, catalyst).
- A Seeking Alpha piece referencing Miplyffa and Europe as a swing factor (GREEN, catalyst).
- An Investing.com report of a $224,948 stock sale by the president and CEO (YELLOW).
Risk watch items include the reported insider sales and the Seeking Alpha framing of Europe as a swing factor. Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.
Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples
Per the Butterfly Supply-Chain Graph, no upstream or downstream dependencies, sector correlations, or proprietary signals are mapped. Not available in source data for supplier, customer, or sector-linkage analysis. Investors should monitor the European commercial outlook referenced in the news feed as the principal open second-order variable.
Open Questions
- What drives the FY 2025 net income of $83.2M given operating income of $-62.9M, and is it recurring?
- What is the company's revenue base, given reported revenue of $0.0M across all periods?
- What is the status of the European market opportunity referenced in the news feed?
- What is the FY 2023 cash and debt position, which is listed as N/A?
- What are the terms and scale of the cash-versus-rival-deal comparison referenced in the news feed?
ZVRA Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Zevra Therapeutics Inc. (ZVRA) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE TradingView • 7h ago
Zevra Therapeutics, Inc. Estimates – NASDAQ:ZVRA TradingView report covering Zevra Therapeutics Inc. (ZVRA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Seeking Alpha • 10h ago
Zevra Therapeutics: Cash Plus A Drug Priced Below Its Rival's Deal (NASDAQ:ZVRA) Seeking Alpha report covering Zevra Therapeutics Inc. (ZVRA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 13h ago
A 20,000-share sale was reported by Zevra Therapeutics (ZVRA) director Neil F. McFarlane. Stock Titan report covering Zevra Therapeutics Inc. (ZVRA) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Stocktwits • 16h ago
ZVRA Stock Hits Its Highest Levels In Nearly 5 Years – What’s Driving This Sharp Rally Today? Stocktwits report covering Zevra Therapeutics Inc. (ZVRA) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Seeking Alpha • 19h ago
Zevra Therapeutics: Miplyffa Validates The Bull Case, Europe Still The Swing Factor (ZVRA) Seeking Alpha report covering Zevra Therapeutics Inc. (ZVRA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com Canada • 22h ago
Zevra Therapeutics president and CEO sells $224,948 in stock By Investing.com Investing.com Canada report covering Zevra Therapeutics Inc. (ZVRA) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST TradingView • 1d ago
Zevra Therapeutics, Inc. Stock 12‑Month Price Target Raised to $25.25, Implies 146% Upside TradingView report covering Zevra Therapeutics Inc. (ZVRA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The Manila Times • 1d ago
Zevra Therapeutics Announces Details for Q3 2026 Financial Results Call The Manila Times report covering Zevra Therapeutics Inc. (ZVRA) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
ZVRA Bull vs. Bear Conversation Board — What's Your Call at $10.28?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ZVRA 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $9.12 (-12.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is ZVRA (D- • RQD 37/100) a Buy at $10.36?
Welcome to the ZVRA (Zevra Therapeutics Inc.) Roar Pit. Current RQD Composite is 37/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $8.60 (-17.0%)
Spot @ $10.36 Pump the brakes on ZVRA — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on ZVRA, but look at what you are paying: 7.4x trailing P/E with tightening sector spreads. Unless Zevra Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH
🎯 Target: $12.43 (+20.0%)
Spot @ $10.36 ZVRA cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on ZVRA, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $10.36 (52-wk range $8.01 - $15.03), any beat on forward guidance forces shorts and underweight funds to chase.